Peplin maintains clinical trial ambitions
Wednesday, 09 February, 2005
Peplin Biotech's (ASX:PEP) half-year results have revealed a AUD$13 million cash balance -- enough, the company says, to complete three Phase II clinical trials of its skin cancer treatment PEP005.
Just over $9.5 million of the balance came from a share issue to existing shareholders and institutions in December. The figures also show a final AUD$1.8 million termination payment from its collaboration with US company Allergan. Research and development expenses during the period rose $0.9 million, in line with increased product development activities, to $6.2 million. Peplin's net loss before and after tax was $4.1 million compared with a net loss of $3.9 million for the corresponding period last year.
After a discouraging second-half of 2004, during which Allergan handed back the rights to PEP005's development, Peplin was boosted recently by a Phase I safety and tolerability trial for PEP005. In 40 per cent of cases, a single application of its PEP005 topical gel for pre-cancerous skin 'sunspots' completely or substantially cleared the volunteers' actinic keratoses (AK), compared with 15 per cent for placebo patients.
"The positive Phase I trial results fundamentally validate our decision late last year to reacquire the product rights and to take forward the clinical trial program on our own," said CEO Michael Aldridge.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...